- Vincent J. Angotti | Chief Executive Officer and Director
- William G. Harris | Senior Vice President of Finance and Chief Financial Officer
- Gregory T. Bates, D.V.M. | Senior Vice President of Regulatory Affairs and Quality
- Richard K. Kim, M.D. | Senior Vice President of Clinical Development and Medical Affairs, and Chief Medical Officer
Vincent J. Angotti | Chief Executive Officer and Director
Vincent J. Angotti was named Chief Executive Officer and joined our board of directors in October 2015. He was previously our executive vice president and chief operating officer from June 2012 to October 2015. Prior to that, Mr. Angotti was senior vice president and chief commercialization officer from May 2008 to June 2012. From 2001 to 2008, he held several positions with Reliant Pharmaceuticals, Inc., the most recent of which was senior vice president of sales and marketing. GlaxoSmithKline acquired Reliant Pharmaceuticals in 2008. Prior to Reliant Pharmaceuticals, from 1991 to 2001, Mr. Angotti held several positions at Novartis Pharmaceuticals Corporation, most recently as executive director, field operations. Mr. Angotti received a B.S. from Cornell University and an M.B.A. from Columbia University.
William G. Harris | Senior Vice President of Finance and Chief Financial Officer
William G. Harris has been our senior vice president of finance and chief financial officer since 2001. From 1996 to 2001, he held several positions with Coulter Pharmaceutical, Inc., the most recent of which was senior vice president and chief financial officer. Corixa Corp. acquired Coulter Pharmaceutical in 2000. Prior to Coulter Pharmaceutical, from 1990 to 1996, Mr. Harris held several positions at Gilead Sciences, Inc., most recently as director of finance. Mr. Harris received a B.A. from the University of California, San Diego and an M.B.A. from Santa Clara University, Leavey School of Business and Administration. Mr. Harris is a member of the board of directors of Capnia, Inc., a publicly-traded commercial stage medical diagnostics and therapeutics company.
Gregory T. Bates, D.V.M. | Senior Vice President of Regulatory Affairs and Quality
Dr. Bates has been our senior vice president of regulatory affairs and quality since June 2012. He was previously our vice president of regulatory affairs from 2006 to June 2012. From 1998 to 2006, Dr. Bates held various positions at Pharmacyclics, Inc, the most recent of which was senior director of regulatory affairs. Prior to Pharmacyclics, in 1998, Dr. Bates was director of regulatory affairs and quality at Otsuka America Pharmaceutical, Inc. From 1995 to 1998, he was manager of regulatory affairs at Genentech, Inc., and from 1990 to 1995, he was senior manager of agribusiness regulatory affairs at Syntex (USA), Inc. Dr. Bates received a B.A. from the University of California, Berkeley and a Doctor of Veterinary Medicine from the University of California, Davis.
Richard K. Kim, M.D. | Senior Vice President of Clinical Development and Medical Affairs, and Chief Medical Officer
Richard K. Kim has been our senior vice president of clinical development and medical affairs, and chief medical officer since January 2014. He was previously our vice president of medical affairs from July 2013 to January 2014. From 2012 to 2013, Dr. Kim was vice president of clinical development and head of the multiple sclerosis therapeutic area, and from 2010 to 2012, he was senior director, clinical development at Elan Pharmaceuticals, Inc. Prior to that, from 2006 to 2010, Dr. Kim was global medical director, medical affairs at Biogen Idec Inc. From 2004 to 2006, he was medical director, clinical development for EMD Serono, Inc. Prior to that, he was associate medical director from 2002 to 2004 at Purdue Pharma L.P. Dr. Kim received a B.S. degree from University of California at Los Angeles and his M.D. from Tulane University. He completed his neurology residency training at Stanford University, and is currently a diplomat of the American Board of Psychiatry and Neurology.